68Ga-PSMA PET in the Renal Cell Carcinoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-90
SponsorXijing Hospital
About this trial
The primary research purpose is to evaluate the diagnostic efficacy of 68Ga-PSMA PET in metastatic lesions of locally advanced and advanced renal cell carcinoma, and to compare with that of enhanced CT. The second purpose is to evaluate whether 68Ga-PSMA PET can change the treatment decision of patients with locally advanced and advanced renal cell carcinoma
Eligibility criteria
Qualifiers
2017 AJCC renal cell carcinoma TNM stage III, IV lesions;
In contrast-enhanced CT staging, suspicious metastases were found;
There were no known peripheral or central venous problems;
68Ga PSMA PET / CT imaging can be performed within 6 weeks after the diagnosis of renal cell carcinoma;
Disqualifiers
Age ≤ 18 years old;
Can't stand lying flat in PET / CT examination;
There are contraindications for 68Ga PSMA ligands;
In the past two years, there was a history of other malignant tumors, or according to the doctor's research judgment, complications may occur and affect the normal operation of the test;
Trial design
Treatments tested in this trial
- PSMA PET
Treatment groups
300 Participants
are divided into 1 treatment groupSponsors and collaborators
Xijing Hospital
Lead sponsor
Air Force Military Medical University, China
Collaborator
Shaanxi Provincial People's Hospital
Collaborator
Yan'an University Affiliated Hospital
Collaborator
Weinan Central Hospital
Collaborator
The Second Affiliated Hospital of Shaanxi University of Chinese Medicine
Collaborator
LanZhou University
Collaborator
Affiliated Hospital of Qinghai University
Collaborator
General Hospital of Ningxia Medical University
Collaborator
Source ClinicalTrials.gov